Floatz logo

Tuvonralimab

CTLA-4

Anhui Provincial HospitalPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the CTLA-4 cohort.

Asset / SponsorPhaseRating
Iparomlimab
Anhui Provincial Hospital
Phase 4BB
LENVATINIB
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
Irinotecan
Anhui Provincial Hospital
Phase 2CCC
(+)-VINCRISTINE
Anhui Provincial Hospital
Phase 2CCC

Same molecule, other indications

Tuvonralimab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
IparomlimabDormant
BB
Indicative ·
65 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →